This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pozen CEO Discusses Q3 2010 Results - Earnings Call Transcript

Pozen, Inc. ( POZN)

Q3 2010 Earnings Call

October 28, 2010 11:00 am ET

Executives

Stephanie Bonestell - IR

John Plachetka - Chairman, President and CEO

Liz Cermak - EVP and COO

Bill Hodges - SVP Finance & Administration and CFO

Analysts

Jonathan Aschoff - Brean Murray

Michael Tong - Wells Fargo

Ian Anderson - Cowen & Company

Eun Yang - Jefferies & Company

Jason Napodano - Zacks Investment Research

Presentation

Operator

Greetings and welcome to the POZEN Incorporated Third Quarter 2010 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions). As a reminder this conference is being recorded.

It is now my pleasure to introduce your host, Stephanie Bonestell, Investor Relations. Thank you Ms. Bonestell. You may begin.

Stephanie Bonestell

Thank you, Rob and good morning. On behalf of POZEN, I would like to welcome everyone to today's third quarter conference call. By now, you should have received a copy of the company's press release. If you do not have it, you can access it on the homepage of our website at www.pozen.com where you can also access the replay of this conference call.

Before we begin, I need to remind you that various remarks that we may make about future expectations, plans and prospects for the company, constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995.

Such statements include, any observations that we may make about the expected timing and amounts of royalty payments from GlaxoSmithKline and AstraZeneca and other revenue expected from our collaboration partners. The prospects for approval or timing of approval of any of our drug candidates or the way in which the FDA may consider our new drug applications or particular trial results, future trial plans and the likelihood of results of any of any future trials, and our potential commercialization plans for our product candidates.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.61 +42.64 0.24%
S&P 500 2,111.89 +2.97 0.14%
NASDAQ 5,056.73 -3.5160 -0.07%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs